by Mohamed Nur Ali, Mustafa Gahnug, Ali Abdi Jama, Mahad Sadik Mukhtar, Mohamed Yaqub Hassan, Farah Ali Ahmed, Yasir Khalif Ali, Farah Abdullahi Ismail, Shuayb Moallim Ali Jama, Nur Adam Mohamed, İbrahim Abukar Abdi, Abdisalam Ismail Hassan, Ismail Gedi Ibrahim, Abdirahman Mohamed Jimale, Mohamed Sheikh Hassan, Said Abdirahman Ahmed
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.